Buy Fulvicin

Fulvicin

What is Fulvicin?

Fulvicin is a brand-name antifungal medication that contains the active ingredient griseofulvin. It is available as a 250 mg oral pill and is prescribed to treat various fungal infections of the skin, hair, and nails. In Hong Kong, Fulvicin is regulated under the Medicines and Poisons Ordinance and is dispensed by prescription only. Griseofulvin belongs to the antifungal therapeutic class, working specifically against dermatophyte fungi that cause conditions such as tinea corporis, tinea pedis, and onychomycosis.

How Fulvicin Works in the Body

Griseofulvin exerts its antifungal effect by binding to fungal microtubules, which disrupts mitosis and prevents the fungus from dividing. This interference with the fungal cell’s structural integrity halts the spread of infection. After oral administration, griseofulvin is well absorbed (approximately 55 % bioavailability) and is concentrated in keratin-rich tissues-skin, hair, and nails-where the fungi reside. The drug’s onset of action typically occurs within a few days, but therapeutic effects become evident over several weeks as the infected keratin is gradually replaced by healthy tissue.

Conditions Treated by Fulvicin

Fulvicin is approved in Hong Kong for the treatment of cutaneous and subcutaneous dermatophyte infections, including:

• Tinea corporis (ringworm of the body)
• Tinea cruris (jock itch)
• Tinea pedis (athlete’s foot)
• Tinea capitis (scalp ringworm)
• Onychomycosis (fungal infection of the nails)

These indications are based on clinical studies demonstrating that griseofulvin effectively eradicates dermatophyte species such as Trichophyton and Microsporum.

Patient Suitability and Contraindications

Who Should Use Fulvicin?

• Adults with confirmed dermatophyte infections who require systemic therapy because topical agents are insufficient.
• Patients with extensive or recurrent infections, or infections involving the scalp or nails.

Absolute Contraindications

• Known hypersensitivity to griseofulvin or any excipients in the pill.
• Pregnancy (Category X): griseofulvin is contraindicated because it can cross the placenta and cause fetal harm.
• Severe hepatic impairment: the drug is primarily metabolized in the liver.

Relative Contraindications

• Mild to moderate liver disease (monitor liver function tests).
• Renal insufficiency (dose adjustments may be needed).
• Concurrent use of drugs that strongly induce hepatic enzymes (e.g., carbamazepine, phenobarbital) may reduce efficacy.
• Elderly patients: may be more prone to hepatic side effects and should be monitored closely.

Special Populations

• Pregnancy & Lactation: Griseofulvin is contraindicated in pregnancy and generally avoided during breastfeeding.
• Pediatric use: Not covered in this article because Fulvicin is marketed for adults in Hong Kong.
• Geriatric patients: Initiate at the lower end of the dosing range and monitor liver function.

Safety Profile and Interactions

Common Side Effects

• Gastrointestinal discomfort (nausea, abdominal cramps) - often mild and transient.
• Headache - typically resolves without intervention.
• Photosensitivity - increased sun sensitivity; patients should wear protective clothing and sunscreen.
• Skin rash - may appear as a mild erythematous eruption.

Serious Adverse Events

• Hepatotoxicity: Elevated liver enzymes or clinical hepatitis; requires immediate medical evaluation.
• Hematologic abnormalities: Rare neutropenia, thrombocytopenia, or anemia.
• Severe photosensitivity reactions (sunburn-like lesions).
• Hypersensitivity reactions: Angioedema or anaphylaxis, though extremely uncommon.

Drug Interactions

• Enzyme inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin) can lower griseofulvin plasma levels, reducing efficacy.
• Warfarin: Griseofulvin may potentiate anticoagulant effects; INR should be monitored closely.
• Oral contraceptives: Griseofulvin can reduce hormonal efficacy, increasing the risk of unintended pregnancy. Alternate contraceptive methods are advised.
• CYP450 interactions: Griseofulvin is metabolized by CYP2C9 and CYP3A4; co-administration with strong inhibitors (e.g., fluconazole) may increase drug exposure.

Food and Lifestyle Interactions

• Fatty meals increase griseofulvin absorption; the medication is usually taken with a high-fat meal to maximize bioavailability.
• Alcohol: May exacerbate liver toxicity; patients with liver disease should limit alcohol intake.
• Sun exposure: Due to photosensitivity, avoid prolonged sun exposure, tanning beds, and use broad-spectrum sunscreen (SPF 30 or higher).
• Driving and machinery: No specific impairment reported; patients experiencing dizziness should exercise caution.

How to Take Fulvicin

• Standard dosing for adults: 500 mg to 1000 mg daily, divided into two doses taken with meals that contain fat. Because Fulvicin is supplied as a 250 mg pill, patients typically take two to four pills per day to reach the recommended total daily dose.
• Duration of therapy: Treatment courses are often 6-12 weeks for skin infections and 6-12 months for nail infections, reflecting the slow growth of keratinized tissue.
• Renal adjustment: For patients with severe renal impairment (creatinine clearance < 30 ml/min), consider dose reduction and close monitoring.
• Hepatic adjustment: In mild to moderate liver disease, start at 500 mg daily and titrate based on tolerance and liver-function tests.
• Administration: Swallow tablets whole with a glass of water; do not crush or chew.
• Missed dose: Take the missed dose as soon as remembered if it is still within a reasonable time frame; otherwise, resume the regular schedule. Do not double the dose.
• Overdose: Symptoms may include nausea, vomiting, abdominal pain, and hepatic dysfunction. Seek emergency medical care; supportive treatment is the mainstay.
• Discontinuation: Abrupt cessation is acceptable; however, a gradual taper is sometimes recommended if the patient has been on high-dose, long-term therapy to monitor for rebound infection.

Monitoring and Follow-Up

• Baseline liver function tests (ALT, AST, bilirubin) before initiating therapy; repeat every 4-6 weeks during treatment.
• Complete blood count (CBC) at baseline and periodically to detect rare hematologic toxicity.
• Clinical assessment of infection response every 4 weeks; adjust therapy duration based on lesion clearance.
• Pregnancy testing is mandatory before starting therapy in women of child-bearing potential due to teratogenic risk.

Storage and Handling

• Store Fulvicin tablets at room temperature (20-25 °C), protected from excess moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication after the expiry date printed on the label.
• For disposal, follow local pharmaceutical waste guidelines or return to a pharmacy for safe collection.

Medication-Specific Glossary

Microsomal Enzyme Induction

The process by which certain drugs increase the activity of liver enzymes (e.g., CYP450), leading to faster metabolism of concurrently administered medications.

Photosensitivity

An increased skin reaction to ultraviolet (UV) radiation, resulting in sunburn-like symptoms after minimal sun exposure.

Keratinized Tissue

Tissue composed primarily of keratin, such as skin, hair, and nails, which provides a niche for dermatophyte fungi and is the primary target of griseofulvin.

Hepatotoxicity

Liver damage caused by a drug, identified by elevated liver enzymes or clinical signs of liver dysfunction.

Medical Disclaimer

This article provides educational information about Fulvicin and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.